TickerFacts.

Entrada Therapeutics, Inc. (TRDA): Free Cash Flow

Operating cash flow minus capital expenditures for the same annual period and currency, computed by TickerFacts from the filed figures. A simple proxy, not a reported figure; a year without both inputs is left out.

-$129.55M
Year ended 2025-12-31
$134.19M2020-12-31: -$27.89M2021-12-31: -$55.44M2022-12-31: -$96.67M2023-12-31: $134.19M2024-12-31: -$44.72M2025-12-31: -$129.55M-$129.55M
2020-12-31 Free Cash Flow (USD) 2025-12-31
Period endedFree Cash FlowChange YoYSource filing
2025-12-31-$129.55Mn/m2026-02-26, From 2025-01-01
2024-12-31-$44.72Mn/m2026-02-26, From 2024-01-01
2023-12-31$134.19Mn/m2025-02-27, From 2023-01-01
2022-12-31-$96.67Mn/m2024-03-13, From 2022-01-01
2021-12-31-$55.44Mn/m2023-03-06, From 2021-01-01
2020-12-31-$27.89Mn/a2022-03-15, From 2020-01-01

Free Cash Flow at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedFree Cash FlowChange YoY
Entrada Therapeutics, Inc. (TRDA)2025-12-31-$129.55Mn/m
Celularity Inc (CELU)2024-12-31-$6.56Mn/m
Alumis Inc. (ALMS)2025-12-31-$370.18Mn/m
Cue Biopharma, Inc. (CUE)2025-12-31-$21.86Mn/m
NewAmsterdam Pharma Co N.V. (NAMS)2025-12-31-$148.03Mn/m
Foghorn Therapeutics Inc. (FHTX)2025-12-31-$86.15Mn/m
Verastem, Inc. (VSTM)2024-12-31-$104.80Mn/a
CASI Pharmaceuticals, Inc. (CASIF)2025-12-31-$20.77Mn/m
Evofem Biosciences, Inc. (EVFM)2025-12-31-$2.00Mn/m

Compare TRDA, CELU, ALMS, CUE side by side · Screen every company in Pharmaceutical Preparations ↗